Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 10/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | EDNRA | P25101 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | VCP | P55072 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | POLG | P54098 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acyclovir SCHEMBL3175 | 1.00 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3664893 | 1.00 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL29531632 | 0.99 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL16061083 | 0.99 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL40724 | 0.99 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL6239258 | 0.99 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL16060281 | 0.99 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL19031784 | 0.99 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL1690304 | 0.99 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL29165535 | 0.97 | PNP (0.95) | PNPBLMHBBUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | LIAONING LIFENG SCIENT & TECHNOLOGY DEV COMPANY LTD (CN) | 2015-06-04 | — | — | US | claimed |
| CN-101716134-B | 2-methoxyestradiol transdermal liniment and 2-methoxyestradiol transdermal patch | UNIV ZHENGZHOU | 2011-08-03 | — | — | CN | claimed |
| CN-101716134-A | 2-methoxyestradiol transdermal liniment and 2-methoxyestradiol transdermal patch | UNIV ZHENGZHOU | 2010-06-02 | — | — | CN | claimed |
| EP-4382122-A1 | PEPTIDE COMPLEX IPF-H2A FOR MODULATION IMMUNE FUNCTION OF THE HUMAN BODY | Zhabilov, Harry H. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20230141965-A1 | TREATMENT OF INFECTIOUS DISEASES | DURECT CORPORATION | 2023-05-11 | — | — | US | disclosed |
| EP-4103195-A1 | TREATMENT OF INFECTIOUS DISEASES | Durect Corporation (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3982927-A1 | TOPICAL ACYCLOVIR FORMULATIONS AND USES THEREOF | Propella Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2021163199-A1 | TREATMENT OF INFECTIOUS DISEASES | DURECT CORPORATION (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2020252252-A1 | TOPICAL ACYCLOVIR FORMULATIONS AND USES THEREOF | PROPELLA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-10322209-B2 | Polyurethanes for osteoimplants | WARSAW ORTHOPEDIC, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180250442-A1 | POLYURETHANES FOR OSTEOIMPLANTS | WARSAW ORTHOPEDIC INC (US) | 2018-09-06 | — | — | US | disclosed |
| EP-0677126-A1 | ANTIVIRAL TOPICAL PHARMACEUTICAL COMPOSITIONS | AGIS INDUSTRIES (1983) LTD (IL) | 1995-10-18 | — | — | EP | disclosed |
| US-5409710-A | Foam cell drug delivery | ENDOCON, INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1994023706-A1 | FOAM CELL DRUG DELIVERY | ENDOCON, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1994015614-A1 | ANTIVIRAL TOPICAL PHARMACEUTICAL COMPOSITIONS | AGIS INDUSTRIES (1983) LIMITED (IL) | 1994-07-21 | — | — | WO | disclosed |
| EP-0584220-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1993023012-A1 | LIQUID-CONTAINING DRUG DELIVERY SYSTEM | ENDOCON, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1992020325-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0400686-A1 | 2-Amino-9-[1,3bis-(isopropoxy)-propyl-2-oxymethyl]-purine, its utilization and medicaments containing it | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-12-05 | — | — | EP | disclosed |
| US-4806341-A | BACKING LAYER, POLYMER MATRIX DISC WITH DRUG MICRODISPERSED THEREIN | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1989-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | CYP11B1, CYP51A1, CYP11B2 | PNP 2457/4885BLM 2884/4885HBB 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.